Primary Sclerosing Cholangitis
Samar H. Ibrahim, M.B., Ch.B., Pediatric-Hepatologist, Mayo Clinic: Hello my name is Samar Ibrahim. I'm one of the pediatric hepatologists at Mayo Clinic. I'm here today to speak about the…
Browsing Tag
Cholangitis
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose…
<!-- Name:DistributionId Value:8840969 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of…
<!-- Name:DistributionId Value:8786540 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Obeticholic Acid Tied to Better Outcomes in Primary Biliary Cholangitis
Patients with primary biliary cholangitis (PBC) on obeticholic acid (Ocaliva) had better…
Machine-learning algorithms can help health care staff correctly diagnose…
Acute cholangitis is a potentially life-threatening bacterial infection that often is associated with gallstones. Symptoms include fever, jaundice, right upper quadrant pain, and elevated…
Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and…
New York, USA, April 27, 2022 (GLOBE NEWSWIRE) -- Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight Primary…
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label,…
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative…
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for…
NEWARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other…
Pinnacle Clinical Research, PLLC Participating in RESPONSE, a Global Phase 3 Clinical…
Novel oral medication could provide a new treatment option for people with PBC who have not achieved the recommended treatment goal or who cannot tolerate first-line therapy that prevents…